AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Irvine, CA, US. The stock last traded at $0.27, up 0.51% on the session, giving a market capitalisation of $12.1M. On trailing twelve-month figures it carries a trailing P/E of -0.05, a net margin of 0.0%. Its beta of 0.64 implies it has historically moved less than the broad market.
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
AEON Biopharma, Inc. is most often compared with the following Healthcare names: